CSPG4 and melanoma: The protocol for the generation of CAR-mRNA-transfected T cells described here is highly feasible, highly reproducible, and performed at a clinical-scale under full GMP compliance, and will be used for a clinical trial with CSPG4-specific CAR-T cells in melanoma patients.